Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
This assessment includes bloodwork such as a lipid panel, glucose, and HbA1c, body composition measurement via DEXA when available, blood pressure, and a functional fitness test
J., Zhuang, X., Tammela, T., Schietinger, A
In the TRIUMPH-4 Phase 3 trial, 39% of participants on the highest Retatrutide dose lost 30% or more of their body weight, and 24% lost 35% or more
Insurance rules, whether you receive a branded or compounded prescription, dose changes as treatment progresses, pharmacy markups, and regional supply constraints are the core drivers of why two people in the same city can see very different bills
a subpotent dose can delay expected benefits and lead to unnecessary dose escalations, and an infection can result in urgent care visits